FDA Reverses Refusal to Review Moderna mRNA Flu Vaccine
- February 20, 2026
The Food and Drug Administration (FDA) will now review Moderna Inc.’s novel flu vaccine that uses mRNA technology for possible approval, walking back its previous refusal from two weeks ago.
ARTICLE TAGS
You must be logged in to access this content.